false 0001544227 0001544227 2026-11-09 2026-11-09 0001544227 TPST:CommonStock0.001ParValueMember 2026-11-09 2026-11-09 0001544227 TPST:SeriesJuniorParticipatingPreferredPurchaseRightsMember 2026-11-09 2026-11-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 9, 2026 

 

Tempest Therapeutics, Inc. 

(Exact name of Registrant as Specified in Its Charter)

 

Delaware   001-35890   45-1472564
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

2000 Sierra Point Parkway, Suite 400    
Brisbane, California   94005
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (415) 798-8589

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 


Title of each class
 
  Trading Symbol(s)    Name of each exchange on
which registered
 
Common Stock, $0.001 par value   TPST   The Nasdaq Stock Market LLC
Series A Junior Participating Preferred Purchase Rights   N/A   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On November 9, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The final results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting are set forth below. These proposals are described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on October 26, 2026 (the “Proxy Statement”).

 

Proposal 1. Election of Directors.

 

The Company’s stockholders elected each of the persons listed below as a Class II director, to serve until the Company’s 2029 Annual Meeting of Stockholders or until his successor is duly elected and qualified or until his earlier death, resignation or removal. The final voting results were as follows:

 

Name  Votes For  Votes Withheld  Broker Non-Votes
John David Yee  9,910,731  235,236  N/A
William Drake Richey  9,840,725  305,242  N/A

 

Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm.

 

The Company’s stockholders ratified the selection of Ernst & Young LLP by the Audit Committee of the Company’s Board of Directors as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results were as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
10,111,485   15,607   18,875   N/A

 

Proposal 3. Approval of the Lincoln Park Stock Issuance Proposal.

 

The Company’s stockholders approved, for purposes of complying with Nasdaq Listing Rule 5635(d), the potential issuance and sale of 20% or more of the Company’s issued and outstanding common stock, par value $0.001 per share (“common stock”), pursuant to the Company’s purchase agreement with Lincoln Park Capital Fund, LLC. The final voting results were as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
9,639,712   490,295   15,960   N/A

 

Proposal 4. Approval of the PIPE Proposal.

 

The Company’s stockholders approved, pursuant to Nasdaq Listing Rule 5635(d), the issuance of up to (A) (i) 3,105,591 shares of common stock issuable upon the exercise of outstanding Series C Warrants and (ii) 3,105,591 shares of common stock issuable upon the exercise of outstanding Series D Warrants, which warrants were issued in connection with the Company’s private placement pursuant to the Securities Purchase Agreement, dated September 11, 2026, by and between the Company and the investor party thereto, and (B) up to 217,391 shares of the Company’s common stock issuable upon the exercise of certain placement agent warrants issued to designees of H.C. Wainwright & Co., LLC, the Company’s placement agent in connection with the private placement. The final voting results were as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
9,636,241   495,192   14,534   N/A

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  TEMPEST THERAPEUTICS, INC.
     
Date: November 10, 2026 By: /s/ Matthew Angel
  Name: Matthew Angel
  Title: Chief Executive Officer

 

2

 


ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

XBRL SCHEMA FILE

XBRL DEFINITION FILE

XBRL LABEL FILE

XBRL PRESENTATION FILE

IDEA: R1.htm

IDEA: FilingSummary.xml

IDEA: MetaLinks.json

IDEA: ea0311733-8k_tempest_htm.xml